Abiraterone Plus Standard Therapy Extends Survival by 1.5 Years in Metastatic Prostate Cancer

Long-term analysis of the Phase 3 PEACE-1 trial, presented at the 2026 European Society for Medical Oncology (ESMO) Congress on October 25, 2026, revealed that adding abiraterone acetate plus prednisone to standard of care significantly extended median overall survival by 1.5 years in patients with de novo metastatic castration-sensitive prostate cancer (CSPC). The median overall survival was 6.1 years with abiraterone compared to 4.6 years without it.